In the most recent trading session, Zoetis (ZTS) closed at $74.81, indicating a +2.37% shift from the previous trading day.
Zoetis (ZTS) reached $69.1 at the closing of the latest trading day, reflecting a -1.05% change compared to its last close.
Zoetis Inc. (ZTS) has fallen 71% from its 2021 peak, now trading at 2017 levels, as pricing power eroded and pet medicine volumes declined. Despite near-term headwinds, Zoetis maintains industry-leading margins and is positioned to weather price wars better than rivals due to its product mix and scale. Patent expiries for Apoquel and Simparica in 2030/2032 are key risks, but a robust pipeline of 12 candidates could offset revenue losses if half succeed.
| Specialty Retail Industry | Consumer Discretionary Sector | Kristin C. Peck CEO | SIX Exchange | US98978V1035 ISIN |
| US Country | 14,500 Employees | 30 Oct 2026 Last Dividend | - Last Split | 1 Feb 2013 IPO Date |
Zoetis Inc. is a global leader in the discovery, development, manufacture, and commercialization of a wide range of animal health medicines, vaccines, and diagnostic products. Founded in 1952 and based in Parsippany, New Jersey, the company addresses the health needs of both livestock—including cattle, swine, poultry, fish, and sheep—and companion animals, such as dogs, cats, and horses. With a presence in both the United States and international markets, Zoetis delivers products and services designed to meet the complex challenges of animal health, ensuring the well-being of animals across the globe. The company's extensive product line-up, alongside innovative diagnostic solutions, makes it a vital player in promoting animal health and supporting the veterinarians, livestock producers, and pet owners who care for them.
Zoetis Inc. offers an expansive portfolio of products and services designed to enhance animal health and support the professionals who work with animals. These include: